Literature DB >> 28653113

Association of soluble ST2 with functional capacity in outpatients with heart failure.

O Yucel1, I Gul2, A Zararsiz2, O Demirpence3, H Yucel2, Z Cinar4, A Zorlu5, M B Yilmaz2.   

Abstract

BACKGROUND: Biomarkers play an important role in the risk stratification of patients with heart failure (HF). Recent studies have shown that soluble suppression of tumorigenicity 2 (sST2), a member of the interleukin 1 receptor family, is associated with disease prognosis in acute and chronic HF. In this study we aimed to investigate the relation between sST2 level and functional capacity in outpatients with systolic HF. PATIENTS AND METHODS: This study included 120 HF patients with reduced ejection fraction (HFrEF; EF ≤ 40%). The mean age of patients was 66 ± 11 years. Advanced HF (New York Heart Association [NYHA] functional class III-IV) was observed in 35 patients (29%).
RESULTS: sST2 levels were on average higher in patients with NYHA functional classes III and IV than in patients with NYHA functional classes I and II (51 [9-198] vs. 25 ng/ml [9-118], p < 0.001). In a multiple logistic regression model, sST2 level (OR: 1.044, p = 0.004, 95% CI: 1.014-1.075), hemoglobin level (OR: 0.590, p = 0.001, 95% CI: 0.433-0.805), total cholesterol level (OR: 0.977, p = 0.004, 95% CI: 0.962-0.993), and age (OR: 1.066, p = 0.047, 95% CI: 1.001-1.136) were associated with poor functional capacity. In receiver operating characteristic (ROC) curve analysis, the optimal cut-off value of sST2 for predicting poor functional capacity was >42 ng/ml, with 63% sensitivity and 88% specificity (AUC: 0.810, 95% CI: 0.728- 0.875).
CONCLUSION: Higher sST2 levels were strongly associated with poor NYHA functional class, independent of cardiac risk factors, in outpatients with HFrEF.

Entities:  

Keywords:  Biomarkers; Exercise tolerance; Hospitalization; Outpatients; Systolic heart failure

Mesh:

Substances:

Year:  2017        PMID: 28653113     DOI: 10.1007/s00059-017-4590-1

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  30 in total

1.  Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study.

Authors:  Peter A McCullough; Edward F Philbin; John A Spertus; Scott Kaatz; Keisha R Sandberg; W Douglas Weaver
Journal:  J Am Coll Cardiol       Date:  2002-01-02       Impact factor: 24.094

2.  Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea.

Authors:  Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi
Journal:  Circ Heart Fail       Date:  2009-05-14       Impact factor: 8.790

3.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

Review 4.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

5.  Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study.

Authors:  Alan Maisel; Yang Xue; Kevin Shah; Christian Mueller; Richard Nowak; W Frank Peacock; Piotr Ponikowski; Martin Mockel; Christopher Hogan; Alan H B Wu; Mark Richards; Paul Clopton; Gerasimos S Filippatos; Salvatore Di Somma; Inder S Anand; Leong Ng; Lori B Daniels; Sean-Xavier Neath; Robert Christenson; Mihael Potocki; James McCord; Garret Terracciano; Dimitrios Kremastinos; Oliver Hartmann; Stephan von Haehling; Andreas Bergmann; Nils G Morgenthaler; Stefan D Anker
Journal:  Circ Heart Fail       Date:  2011-07-15       Impact factor: 8.790

6.  High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Kristin McCloskey; J Eduardo Rame; Erin McIntosh; Puja Shahi; Daniel L Dries; W H Wilson Tang; Alan H B Wu; James C Fang; Rebecca Boxer; Nancy K Sweitzer; Wayne C Levy; Lee R Goldberg; Mariell Jessup; Thomas P Cappola
Journal:  Circ Heart Fail       Date:  2010-12-22       Impact factor: 8.790

7.  Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis.

Authors:  Alberto Aimo; Giuseppe Vergaro; Claudio Passino; Andrea Ripoli; Bonnie Ky; Wayne L Miller; Antoni Bayes-Genis; Inder Anand; James L Januzzi; Michele Emdin
Journal:  JACC Heart Fail       Date:  2016-11-02       Impact factor: 12.035

Review 8.  Soluble ST2--analytical considerations.

Authors:  Thomas Mueller; Allan S Jaffe
Journal:  Am J Cardiol       Date:  2015-01-23       Impact factor: 2.778

9.  Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.

Authors:  Domingo A Pascual-Figal; Jordi Ordoñez-Llanos; Pedro L Tornel; Rafael Vázquez; Teresa Puig; Mariano Valdés; Juan Cinca; Antoni Bayes de Luna; Antoni Bayes-Genis
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

10.  Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.

Authors:  Thomas Mueller; Benjamin Dieplinger; Alfons Gegenhuber; Werner Poelz; Richard Pacher; Meinhard Haltmayer
Journal:  Clin Chem       Date:  2008-04       Impact factor: 8.327

View more
  3 in total

1.  Suppression tumorigenicity 2 (ST2) turbidimetric immunoassay compared to enzyme-linked immunosorbent assay in predicting survival in heart failure patients with reduced ejection fraction.

Authors:  Lindsey Aurora; Edward Peterson; Hongsheng Gui; Nicole Zeld; James McCord; Yigal Pinto; Bernard Cook; Hani N Sabbah; L Keoki Williams; James Snider; David E Lanfear
Journal:  Clin Chim Acta       Date:  2020-09-12       Impact factor: 3.786

2.  Author`s Reply.

Authors:  İbrahim Gül; Oğuzhan Yücel; Abdullah Zararsız; Özlem Demirpençe; Hasan Yücel; Ali Zorlu; Mehmet Birhan Yılmaz
Journal:  Anatol J Cardiol       Date:  2018-03       Impact factor: 1.596

3.  Association of Soluble Suppression of Tumorigenesis-2 (ST2) with Endothelial Function in Patients with Ischemic Heart Failure.

Authors:  Stathis Dimitropoulos; Vasiliki Chara Mystakidi; Evangelos Oikonomou; Gerasimos Siasos; Vasiliki Tsigkou; Dimitris Athanasiou; Nikolaos Gouliopoulos; Evanthia Bletsa; Aimilios Kalampogias; Georgios Charalambous; Costas Tsioufis; Manolis Vavuranakis; Dimitris Tousoulis
Journal:  Int J Mol Sci       Date:  2020-12-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.